新型糖氨基酸类化合物的合成研究

糖氨基酸(sugar amino acids, SAAs)是一类同时含有氨基和羧基的糖类衍生物, 具有糖和氨基酸的结构特征和化学反应特性, 常作为多功能合成砌块用于组合化学的研究、糖模拟物和多肽模拟物的构建等. 因此, 该类化合物的设计与合成受到国内外化学家的持续关注. 在本文中, 我们发展了一种简单、高效的合成新型糖氨基酸的方法, 从廉价易得的3,4,6-O-三乙酰基-D-葡萄糖烯和3,4,6-O-三乙酰基-D-半乳糖烯出发, 在硝酸铈铵(CAN)的作用下通过一步自由基加成反应分别得到2-C-二羧酸酯类化合物gluco-2和galacto-2, 再经过脱羧、脱乙酰、碘代、叠氮化钠取代和一锅法还原氨化反应, 以最短直线步骤6步实现了糖氨基酸gluco-7(总收率34%)和galacto-7(总收率19%)的合成. 所有合成的化合物均经过IR, ¹H NMR, ¹³C NMR和HRMS的表征.     

植物用抗病毒剂的研究——含氟苯甲酸糖酯的合成

通过相转移催化反应,在氢氧化钠和相转移催化剂四丁基溴化铵存在下,将含氟苯甲酸分别与O－乙酰基溴代葡萄糖、O－乙酰基溴代半乳糖、O－乙酰基溴代乳糖和O－乙酰基溴代木糖作用,合成了14个未见文献报道的新化合物－含氟苯甲酸乙酰基糖酯。由IR,MS和^1HNMR确认了这些新的糖酯的结构及β构型。     

相转移催化法合成1-O-酰基-四-O-乙酰基-β-D-吡喃己糖

以氯化三乙基苄基铵作为相转移催化剂, 用2, 3, 4, 6-四-O-乙酰基-β-D-溴代吡喃葡萄糖和2, 3, 4, 6-四-O-乙酰基-β-D-溴代吡喃半乳糖与羧酸反应, 合成了相应的1-O-酰基-2, 3, 4, 6-四-O-乙酰基-β-D-吡喃葡萄糖和半乳糖。通过解析这些化合物的^1H NMR和红外光谱, 确证其糖甙键构型为β。该相转移催化法具有反应条件温和, 后处理简单和立体选择性强等优点。     

N-茄呢基胺类糖酯化合物的合成及生理活性

在氢氧化钠和四丁基溴化铵存在下,将化合物2-N-茄呢基胺基苯甲酸(3)和N-茄呢基己二酰胺酸(6)分别与O-乙酰基溴代葡萄糖、O-乙酰基溴代半乳糖、O-乙酰基溴代乳糖和O-乙酰基溴代麦芽糖反应制得对应的糖酯4a～4d和7a～7d,由元素分析,IR,1H NMR和MS确证了8个新化合物的结构,并对其中6个化合物(4a,4d和7a～7d)在三种癌细胞模型上进行了一些初步体外生理活性的测试.     

水杨酸葡聚七糖苷缀合物的合成及生物活性研究

为了研究不同植物诱导剂之间的协同作用, 我们以水杨酸甲酯为原料与6-O-乙酰基-2,3,4-三-O-苯甲酰基-α-D-吡喃葡萄糖苷三氯乙酰亚胺酯偶联得化合物5, 然后脱去6-位乙酰基得受体化合物6, 化合物6与葡聚六糖三氯乙酰亚胺酯供体7偶联, 脱保护后得到葡聚七糖与水杨酸的缀合物1. 生物活性研究结果表明, 葡聚七糖还原端连有水杨酸的糖缀合物诱导植物抗病活性要比相应的七糖2高.     

九子参中三个糖链上带乙酰基的新三萜皂苷-九子参苷B, C, D

从石竹科植物九子参(Silene rubicunda)根中得到四个糖链上带乙酰基的新的三萜皂苷——九子参苷A,B,C,D(rubicunosides A～D,1～4).前文已详细报道了九子参苷A的结构研究,本文报道九子参苷B,C,D的结构.通过FAB-MS和NMR,分别确定九子参苷B,C,D为糖链上带单乙酰基的三萜九糖苷、七糖苷和糖链上带双乙酰基的三萜八糖苷,分别命名为皂树酸-3-O-β-D吡喃半乳糖-(1→2)-[β-D-吡喃木糖-(1→3)]-β-D-吡喃葡萄糖醛酸-28-O-β-D-吡喃木糖-(1→3)-β-D-吡喃木糖-(1→4)-a-L-吡喃鼠李糖-(1→4)-[β-D-吡喃葡萄糖-(1→4′)-β-D-吡喃鸡纳糖-(1→2)]-[3′-O-乙酰基]-β-D-吡喃夫糖苷(九子参苷B,2),皂树酸-3-O-β-D-吡喃半乳糖-(1→2)-[β-D-吡喃木糖-(1→3)]-β-D-吡喃葡萄糖醛酸-28-O-β-D-吡喃木糖-(1→4)-a-L-吡喃鼠李糖-(1→4)-[4″-O-乙酰基-β-D-吡喃葡萄糖-(1→2)]-β-D-吡喃夫糖苷(九子参苷C,3),皂树酸-3-O-β-D-吡喃半乳糖-(1→2)-[β-D-吡喃木糖-(1→3)]-[6′-O-正丁基]-β-D-吡喃葡萄糖醛酸-28-O-β-D-吡喃木糖-(1→3)-β-D-吡喃木糖-(1→4)-a-L-吡喃鼠李糖-(1→4)-[2″-O-乙酰基-β-D-吡喃鸡纳糖-(1→2)]-[3′-O 乙酰基]-β-D-吡喃夫糖苷(九子参苷D,4).     

异维A酸糖基衍生物的合成及其细胞毒活性研究

采用两种方法合成了2类新的异维A酸糖基衍生物(5a~5d, 6a, 10a~10c, 11a), 并进行了结构表征与确认. 采用MTT法测试了它们对肺癌细胞(A549)等的细胞毒活性. 结果显示, 含有糖苷结构的异维A酸衍生物明显比含有糖酯结构的异维A酸衍生物具有更好的细胞毒活性; 将糖环上的乙酰基脱去后, 相应的化合物活性有明显提高.     

N,N—二（邻硝基苯氨基乙基）甘氨酸糖酯的合成

在氢氧化钠和四丁基溴化铵存在下，将Ｎ，Ｎ－二（邻硝基苯氨基乙基）甘氨酸分别与Ｏ－乙酰基代葡萄糖，Ｏ－乙酰基溴代半乳糖，Ｏ－乙酰基溴代乳糖和Ｏ－乙酰基溴代木糖作用，制得Ｎ，Ｎ－二取代甘氨酸的对应乙酰基糖酯。由元素分析，ＩＲ，ＭＳ和Ｈ＾１Ｈ ＮＭＲ确认了４个的糖酯的结构。     

N,N-二(邻硝基苯氨基乙基)甘氨酸糖酯的合成

在氢氧化钠和四丁基溴化铵存在下,将N,N-二(邻硝基苯氨基乙基)甘氨酸分别与O-乙酰基溴代葡萄糖、O-乙酰基溴代半乳糖、O-乙酰基溴代乳糖和O-乙酰基溴代木糖作用,制得N,N-二取代甘氨酸的对应乙酰基糖酯。由元素分析、IR、MS和¹HNMR确认了4个的糖酯的结构。关键词N,N-二(邻硝基苯氨基乙基)甘氨酸糖酯,溴代葡萄糖,溴代乳糖,溴代木糖,葡萄糖酸酯。     

流动注射-分光光度法同时测定食品中水溶性总糖和还原糖

食品中水溶性总糖经1mol.L-1盐酸溶液水解生成还原糖,对羟基苯甲酸酰肼与生成的还原糖显色,在波长420nm处有最大吸收峰,据此提出了一种流动注射-分光光度法测定食品中水溶性总糖和还原糖含量的方法。方法的线性范围为50.0～800mg.L-1,还原糖的检出限为5.32mg.L-1,总糖的检出限为2.71mg.L-1。方法用于食品中还原糖和水溶性总糖的测定,测得方法的回收率在98.0%～101%之间,测定值的相对标准偏差(n=6)在1.1%～1.5%之间。     

异环二取代二茂铁衍生物的合成

从芳基二茂铁的汞化产物中首次分离出四种异环二取代产物 1-氯汞基-1'-芳基二茂铁。1-氯汞基-1'-芳基二茂铁与碘作用得到四种相应的碘代产物。氯汞基二茂铁及1-氯汞基-1'-芳基二茂铁经[ClRh(CO)~2]~2 催化偶联反应制得联二茂铁和三种1'、1''-二芳基联二茂铁。以上化合物的组成与结构经元素分析、IR 和^1H NMR确证, 其中10种为新化合物。     

1-(3,5-二甲基苯基)-1-[(1S,4S)-1,7,7-三甲基双环[2.2.1]庚烷-2-基]肼的合成工艺改进

以3,5-二甲基苯胺和2-莰酮为起始原料,在微波促进下,经缩合反应制得N-(3,5-二甲基苯基)-1-(1S,4S)-1,7,7-三甲基二环[2.2.1]庚烷-2-亚胺(1);1经硼氢化钠还原后再与羟胺-O-磺酸经胺化反应合成了1-(3,5-二甲基苯基)-1-[(1S,4S)-1,7,7-三甲基双环[2.2.1]庚烷-2-基]肼,总收率70.4%,其结构经1H NMR和ESI-MS确证。     

Regulation of chicken protein tyrosine phosphatase 1 and human protein tyrosine phosphatase 1B activity by casein kinase II- and p56lck-mediated phosphorylation

Protein tyrosine phosphorylation and dephosphorylation are important in the regulation of cell proliferation and signaling cascade. In order to examine whether phosphatase activity of CPTP1 and HPTP1B, typical nontransmembrane protein tyrosine phosphatase, could be controlled by phosphorylation, affinity-purified PTPs were phosphorylated by CKII and p56lck in vitro. Phosphoamino acid analysis revealed that CPTP1 was phosphorylated on both serine and threonine residues by CKII, and tyrosine residue by p56lck. Phosphatase activity of CPTP1 was gradually increased by three-fold concomitant with phosporylation by CKII. Phosphorylation of HPTP1B by CKII resulted in quick two-fold enhancement of its phosphatase activity within 5 min of incubation and remained in that state. In the presence of CKII inhibitor, heparin or poly(Glu.Tyr), both phosphorylation and enhancement of phosphatase activity of CPTP1 and HPTP1B were mostly blocked. p56lck catalyzed tyrosine phosphorylation of CPTP1 and HPTP1B was only observed by inhibiting the intrinsic tyrosine phosphatase activity. Taken together, these results indicate that CPTP1 or HPTP1B possesses a capability to regulate its phosphatase activity through phosphorylation processes and may participate in the cellular signal cascades.     

抗菌肽SAMP1及其类似肽的构效关系

以人工合成抗菌肽1(Synthetic antimicrobial peptide 1, SAMP1)为研究模板, 采用氨基酸序列重排、 不同的带正电荷氨基酸残基和疏水性氨基酸残基取代等方法, 设计合成了8条SAMP1类似肽. 利用生物信息学软件预测了SAMP1及其类似肽的理化性质; 采用圆二色光谱(CD)技术测定其在不同环境下二级结构的变化; 采用噻唑蓝(MTT)法测定其抗菌活性; 通过红细胞溶血实验评估了这些多肽的溶血性. 结果表明, 大部分类似肽具有较低的溶血毒性和较高的广谱抗菌活性. CD光谱分析结果显示, 大部分类似肽二级结构以α螺旋和无规则卷曲为主, 在体积分数为50%的2,2,2-三氟乙醇(TFE)溶液中, α螺旋结构比例增加. 与母肽SAMP1相比, 经序列重排后得到的SAMP1-A1, SAMP1-A2和SAMP1-A3的抗菌活性变化不大, 但序列中正电荷氨基酸残基均匀分布的类似肽SAMP1-A2的溶血毒性增加. 用精氨酸(Arg)取代SAMP1序列中的赖氨酸(Lys)得到的类似肽SAMP1-A4的抗菌活性增强, 同时溶血毒性降低. 用疏水性较强的异亮氨酸(Ile)和缬氨酸(Val)取代SAMP1中的疏水性氨基酸残基, 得到的类似肽SAMP1-A5和SAMP1-A7的抗菌活性急剧降低; 用疏水性较弱的色氨酸(Trp)取代SAMP1中的疏水性氨基酸残基, 得到的类似肽SAMP1-A8的抗菌活性增强, 同时溶血毒性提高.     

(Z)-1-[2-(三苯基锡基)乙烯基]-1-茚满醇及其酯和卤代物的合成与表征

在氮气保护下,1-乙炔茚满醇与三苯基氢化锡进行游离基加成反应,获得加成物(Z)-1-[2-(三苯基锡基)乙烯基]-1-茚满醇(1);将加成物(1)与苯酐反应,得到新型邻苯二甲酸单酯有机锡衍生物(2);衍生物(2)分别与二丁基氧化锡和三苯基氧化锡进行脱水反应,分别获得两个新型邻苯二甲酸酯的有机锡衍生物(3)和(4).将加成物(1)与卤素反应后,与锡原子直接相连的苯基被取代,得到一卤代和二卤代物(5～10).通过元素分析、¹HNMR和IR等手段对化合物1～10进行了结构表征,确定了该类邻苯二甲酸单酯和邻苯二甲酸酯的有机锡衍生物的结构.并测定了加成物(1)和一溴代物(6)的晶体结构,在加成物(1)中,由于分子内存在较弱的O→Sn[0.2778(8)nm]配位作用,锡原子呈扭曲三角双锥构型.在一溴代物(6)分子中,存在分子内O→Sn[0.2364(2)nm]配位键,锡原子呈扭曲的三角双锥构型.该系列化合物分子内的O→Sn配位能力和Lewis酸性强弱的顺序为:二卤化物>一卤化物>加成物;氯代物>溴代物>碘代物>加成物.     

Phosphorylation of phospholipase D1 and the modulation of its interaction with RhoA by cAMP-dependent protein kinase

Agents that elevate cellular cAMP are known to inhibit the activation of phospholipase D (PLD). We investigated whether PLD can be phosphorylated by cAMP-dependent protein kinase (PKA) and PKA-mediated phosphorylation affects the interaction between PLD and RhoA, a membrane regulator of PLD. PLD1, but not PLD2 was found to be phosphorylated in vivo by the treatment of dibutyryl cAMP (dbcAMP) and in vitro by PKA. PKA inhibitor (KT5720) abolished the dbcAMP-induced phosphorylation of PLD1, but dibutyryl cGMP (dbcGMP) failed to phosphorylate PLD1. The association between PLD1 and Val14RhoA in an immunoprecipitation assay was abolished by both dbcAMP and dbcGMP. Moreover, RhoA but not PLD1 was dissociated from the membrane to the cytosolic fraction in dbcAMP-treated cells. These results suggest that both PLD1 and RhoA are phosphorylated by PKA and the interaction between PLD1 and RhoA is inhibited by the phosphorylation of RhoA rather than by the phosphorylation of PLD1.     

PD-1与单克隆抗体残基特异性结合机制的计算丙氨酸扫描研究

通过分子动力学模拟检测了2种程序性细胞死亡蛋白(PD-1)/单克隆抗体(Pembrolizumab和Nivolumab)复合物,并使用高效的计算丙氨酸扫描方法预测了单抗与PD-1的结合热点,将它们与对PD-1/PD-L1结合重要的热点残基进行对比分析.结果显示, Pembrolizumab以类似于PD-L1的方式与PD-1结合,而Nivolumab则以不同的方式与PD-1结合. 2个PD-1/mAb复合物中共有的热点只有PD-1K131.同时发现,与PD-1K131结合的单抗的关键残基通常都受范德华(vdW)能量控制. 2种单克隆抗体上热点的自由能贡献都以vdW能量为主,这表明在下一代PD-1新抗体的设计中需要提高静电型热点残基的数量.     

Fragmentation of carbohydrate anomeric alkoxy radicals: a new synthesis of chiral 1-halo-1-iodo alditols

Treatment of 1,2-fluorohydrins, 1,2-chlorohydrins, 1,2-bromohydrins, and 1,2-iodohydrins of the D-gluco, D-galacto, D-lacto, L-rhamno, D-allo, L-arabino, 3-deoxy-D-gluco, and 3,4-dideoxy-D-gluco families of carbohydrates with the (diacetoxyiodo)benzene/iodine system afforded 1-fluoro-1-iodo, 1-chloro-1-iodo, 1-bromo-1-iodo, and 1,1-diiodo alditols, respectively, in excellent yields. The reaction was achieved by radical fragmentation of the C1bond;C2 bond, triggered by the initially formed anomeric alkoxy radical, and subsequent trapping of the C2-radical by iodine atoms. This methodology is compatible with the stability of the protective groups most frequently used in carbohydrate chemistry. The potential utility of these 1-halo-1-iodo alditols as chiral synthons was evaluated by their transformation into alk-1-enyl iodides and in the Takai E-olefination reaction.     

Purification of Complex of SAV1 with PP1A

SAV1 is a core component involved in the Hippo pathway which can control the organ size via regulating cell proliferation and apoptosis simultaneously. We explored the regulatory mechanism of SAV1. We established the HEK293T cell pool, the cells in which can stably express SAV1 by retroviruses infection and found that SAV1 stable cells reduced the movement of themselves and resulted in multicellular aggregation. We purified SAV1 interacting protein complex using streptavidin resin and subsequently analyzed the digested peptides by high performance liquid chromatography(HPLC)-MS/MS. Results show that about 150 proteins were identified in the complex of SAV1 with protein. TUBA1A, OTUD4, and ATD were identified as proteins interacting with SAV1. Importantly, PP1A, serine/threonine protein phosphatase PP1-alpha 1 catalytic subunit, was also in the top 10 list. The interaction between PP1A and SAV1 was detected by both co-immunoprecipitation(CO-IP) and immunostaining. Our results indicate that PP1A might be the phosphatase of SAV1 and may take part in the regulation of the Hippo pathway.